Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...
BusinessWire India Mumbai Maharashtra Hyderabad Telangana [India] October 30 PopVax an Indian full-stack biotechnology ...
Oppenheimer analyst Jay Olson maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of $70.00. The company’s shares closed yesterday at $15.85.
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) and keeping the price target at $57.00. Terence Flynn’s rating is based on ...
Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...
The clinical-stage biopharmaceutical company, Seaport Therapeutics, which uses a unique drug delivery platform originally developed by Monash University, has announced the closing of an oversubscribed ...
Nanovation Therapeutics, Olympus Medical, Pulmonx, Roche Diagnostics, and Uptake Medical. Korn has received research support from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GSK, Novartis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback